Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy

References

• Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–375. doi:10.1093/jnci/djk06417341728
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017. doi:10.1001/jamainternmed.2015.118025915855
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235–243. doi:10.1200/JCO.2015.63.444426573075
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199.25601342
   PubMed Web of Science ®Google Scholar
• Tucker SL, Liu A, Gomez D, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016;119(3):495–500. doi:10.1016/j.radonc.2016.04.02527189523
   PubMed Web of Science ®Google Scholar
• Speirs CK, DeWees TA, Rehman S, et al. Hart dose is an independent dosimetric predictor of OS in LA NSCLC. J Thorac Oncol. 2017;12(2):293–301. doi:10.1016/j.jtho.2016.09.13427743888
   PubMed Web of Science ®Google Scholar
• Wang K, Eblan MJ, Deal AM, et al. Marks cardiac toxicity after radiotherapy for stage III non–small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35(13):1387–1394. doi:10.1200/JCO.2016.70.022928113017
   PubMed Web of Science ®Google Scholar
• Stam B, van der Bijl E, van Diessen J, et al. Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy. Radiother Oncol. 2017;125(1):62–65. doi:10.1016/j.radonc.2017.09.00428939179
   PubMed Web of Science ®Google Scholar
• McWilliam A, Kennedy J, Hodgson C, et al. Radiation dose to heart base linked with poorer survival in lung cancer patients. Eur J Cancer. 2017;85:106–113. doi:10.1016/j.ejca.2017.07.05328898766
   PubMed Web of Science ®Google Scholar
• Cella L, D’Avino V, Palma G, et al. Modeling the risk of radiation-induced lung fibrosis: irradiated heart tissue is as important as irradiated lung. Radiother Oncol. 2015;117(1):36–43. doi:10.1016/j.radonc.2015.07.05126277435
   PubMed Web of Science ®Google Scholar
• Oh P, Zhang M, Brady P, et al. Impact of lung and heart dose on survival after radiotherapy for esophageal cancer. J Clin Oncol. 2018;36(4 suppl):3. doi:10.1200/JCO.2018.36.4_suppl.3
   Web of Science ®Google Scholar
• Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011;117(13):3004–3013. doi:10.1002/cncr.2584821264827
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1087–1096. doi:10.1016/j.ijrobp.2006.01.05216682145
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements. ICRU Reports 62 (Supplement to ICRU Report 50). Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda (MD): ICRU; 1999.
   Google Scholar
• Jin X, Xie C. Dosimetric and clinical benefits of conformal radiotherapy plus volumetric modulated arc therapy in the treatment of non-small cell lung cancer. Med Phys. 2015;42(6):3704–3705. doi:10.1118/1.4926135
   Web of Science ®Google Scholar
• Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;6(7):1025–1039. doi:10.1016/j.jaad.2012.02.010
   Google Scholar
• Bree I, van Hinsberg MG, van Veelen LR. High-dose radiotherapy in inoperable non-small cell lung cancer: comparison of volumetric modulated arc therapy, dynamic IMRT and 3D conformal radiotherapy. Med Dosim. 2012;37:353–357. doi:10.1016/j.meddos.2011.12.00222459649
   PubMed Web of Science ®Google Scholar
• Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 2008;87:17–23. doi:10.1016/j.radonc.2008.02.00518343515
   PubMed Web of Science ®Google Scholar
• Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102. doi:10.1016/j.ijrobp.2006.12.03117321067
   PubMed Web of Science ®Google Scholar
• Liao ZX, Komaki RR, Thames HD Jr, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:775–781. doi:10.1016/j.ijrobp.2009.02.03219515503
   PubMed Web of Science ®Google Scholar
• Nalbantov G, Kietselaer B, Vandecasteele K, et al. Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol. 2013;109:100–106. doi:10.1016/j.radonc.2013.08.03524044794
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Ball D, Jett JR, et al. Non-small- cell lung cancer. Lancet. 2011;378:1727–1740. doi:10.1016/S0140-6736(11)60984-721565398
   PubMed Web of Science ®Google Scholar
• Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three dimensional conformal radiotherapy (3-DCRT). Int J Radiat Oncol Biol Phys. 2006;66:1399–1407. doi:10.1016/j.ijrobp.2006.07.133716997503
   PubMed Web of Science ®Google Scholar
• Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67:275–283.12865175
   PubMed Web of Science ®Google Scholar
• Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001;49:649–655.11172945
   PubMed Web of Science ®Google Scholar
• Minami-Shimmyo Y, Ohe Y, Yamamoto S, et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol. 2012;7:177–182. doi:10.1097/JTO.0b013e31823c4c0722134071
   PubMed Web of Science ®Google Scholar
• Cosset JM, Henry-Amar M, Girinski T, Malaise E, Dupouy N, Dutreix J. Late toxicity of radiotherapy in Hodgkin’s disease. The role of fraction size. Acta Oncol. 1988;26:123–129. doi:10.3109/02841868809090332
   Google Scholar
• Brenner DJ, Shuryah I, Jozsef G, DeWyngaert KJ, Formenti SC. Risk and risk reduction of major coronary events associated with contemporary breast RT. JAMA Intern Med. 2014;174:158–160. doi:10.1001/jamainternmed.2013.1179024166078
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Brodin P, Aznar MC, et al. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment? Int J Radiat Oncol Biol Phys. 2013;87:297–303. doi:10.1016/j.ijrobp.2013.06.00423910709
   PubMedGoogle Scholar
• Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24:2113–2118. doi:10.1093/annonc/mdt15623619032
   PubMed Web of Science ®Google Scholar
• Hatakenaka M, Yonezawa M, Nonoshita T, et al. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys. 2012;83:e67–e73. doi:10.1016/j.ijrobp.2011.12.01822365626
   PubMed Web of Science ®Google Scholar